Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 18/20 | 0.63 |
| ▸ | ADK | P55263 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30404376 | 1.00 | SRC (0.63) | SRCADKEGFR | |
| SCHEMBL26791254 | 0.90 | SRC (0.64) | SRCEGFR | |
| SCHEMBL30403393 | 0.89 | SRC (0.52) | SRCADK | |
| SCHEMBL26789849 | 0.89 | SRC (0.52) | SRCADK | |
| SCHEMBL31463180 | 0.86 | SRC (0.58) | SRCEGFR | |
| SCHEMBL30035929 | 0.86 | SRC (0.58) | SRCEGFR | |
| SCHEMBL15345656 | 0.85 | SRC (0.63) | SRCEGFR | |
| SCHEMBL15345657 | 0.85 | SRC (0.63) | SRCEGFR | |
| SCHEMBL26789839 | 0.85 | ADK (0.48) | SRCADK | |
| SCHEMBL26806680 | 0.85 | ADK (0.48) | SRCADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. | 2023-11-23 | — | — | US | disclosed |
| EP-4161657-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | Kinnate Biopharma Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | FGFR1, FGFR2, FGFR3 | SRC 30/4885ADK 374/4885EGFR 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.